Ingenol mebutate 0·015% gel is safe for short-term treatment of actinic keratoses on the face in solid organ transplant recipients.

Crow, L D; Yuan, J T; Aroyan, C S; Twigg, A R; Singer, J P; Roll, G R; Lazar, A A; Arron, S T

Crow, L D; Yuan, J T; Aroyan, C S; Twigg, A R; Singer, J P; Roll, G R; Lazar, A A; Arron, S T.

Afiliación

Crow LD; Department of Dermatology, University of California San Francisco, San Francisco, CA, USA.
Yuan JT; Department of Dermatology, University of California San Francisco, San Francisco, CA, USA.
Aroyan CS; Department of Dermatology, University of California San Francisco, San Francisco, CA, USA.
Twigg AR; Department of Dermatology, University of California San Francisco, San Francisco, CA, USA.
Singer JP; Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
Roll GR; Department of Surgery, Division of Transplant, University of California San Francisco, San Francisco, CA, USA.
Lazar AA; Department of Preventive and Restorative Dental Sciences, University of California San Francisco, San Francisco, CA, USA.
Arron ST; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA.

Br J Dermatol ; 183(3): 575-577, 2020 09.

Article en En | MEDLINE | ID: mdl-32221965

Asunto(s)

Antineoplásicos; Diterpenos; Queratosis Actínica; Antineoplásicos/uso terapéutico; Cara; Geles/uso terapéutico; Humanos; Queratosis Actínica/tratamiento farmacológico; Resultado del Tratamiento

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Diterpenos / Queratosis Actínica / Antineoplásicos Límite: Humans Idioma: En Revista: Br J Dermatol Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google